Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of Glanzmann’s thrombasthenia caused by a missense mutation Gly₅₄₀Asp on β3

Summary

Treatment of bleeding in patients with Glanzmann’s thrombasthenia (GT) can be hampered by iso-antibodies against the αIIbβ3 integrin, which cause rapid clearance of transfused donor platelets. Type 1 GT patients with a total absence of αIIbβ3 from the platelet surface are known to be susceptible to form such isoantibodies. In this study, we describe a type 1 GT patient with a missense mutation (Gly₅₄₀Asn) located in the EGF3 domain of the β3 integrin subunit. Cotransfection analysis in CHO cells demonstrates total absence of αIIbβ3 from the surface, based on inappropriate αIIb maturation. The patient’s serum was reactive with αIIbβ3 and αvβ3 integrins in a capture assay, when platelets and endothelial cells were used. Two specificities could be isolated from the patient’s serum, anti-αIIbβ3 and anti-αvβ3 isoantibodies. Both specificities did not interfere with platelet aggregation. In contrast, isoantibodies against αvβ3, but not against αIIbβ3, were able to disturb endothelial cell adhesion onto vitronectin, triggered endothelial cell apoptosis and interfered with endothelial tube formation. This intriguing finding may explain more recently observed features of fetal/neonatal iso-immune thrombocytopenia in children from type 1 GT mothers with intracranial haemorrhage, which could be related to anti-endothelial activity of the maternal antibodies. In conclusion, we give evidence that two isoantibody entities exist in type 1 GT patients, which are unequivocally different, both in an immunological and functional sense. Further research on the clinical consequences of immunisation against αvβ3 is required, predominantly in GT patients of childbearing age.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Glanzmann’s thrombasthenia - platelet function defect - isoimmunisation - αvβ3

• References

• 1 Nurden AT, Fiore M, Nurden P. et al. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
• 2 Sandrock K, Halimeh S, Wiegering V. et al. Homozygous point mutations in platelet glycoprotein ITGA2B gene as cause of Glanzmann thrombasthenia in 2 families B. Klin Padiatr 2012; 224: 174-178.
• 3 Fiore M, Firah N, Pillois X. et al. Natural history of platelet antibody formation against αiibβ3 in a french cohort of glanzmann thrombasthenia patients. Haemophilia 2012; 18: 201-209.
• 4 Tokgoz H, Ozkan TD, Caliskan U. et al. Novel mutations of integrin αIIb and β3 genes in Turkish children with Glanzmann's thrombasthenia. Platelets 2015; 26: 779-782.
• 5 Franchini M, Favaloro EJ, Lippi G.. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010; 411: 1-2.
• 6 Nurden AT.. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 6: 1-10.
• 7 Poon MC, Zotz R, Minno GD. et al. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43 (01) (Suppl. 01) S33-36.
• 8 Kashiwagi H, Kiyomizu K, Kamae T. et al. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-αIIbβ3 alloantibodies. Int J Hematol 2011; 93: 106-111.
• 9 Santoro C, Rago A, Biondo F. et al. Prevalence of allo-immunisation anti-HLA and anti-integrin αIIbβ3 in Glanzmann Thromboasthenia patients. Haemophilia 2010; 16: 805-812.
• 10 Fiore M, Firah N, Pillois X. et al. Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 2012; 18: e201-e209.
• 11 Léticée N, Kaplan C, Lémery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk?. Eur J Obstet Gynecol Reprod Biol 2005; 121: 139-142.
• 12 Siddiq S, Clark A, Mumford A.. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-869.
• 13 Grimaldi CM, Chen F, Wu C. et al. Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-1571.
• 14 Santoso S, Zimmermann U, Neppert J. et al. Receptor patching and capping of platelet membranes induced by monoclonal antibodies. Blood 1986; 67: 343-349.
• 15 Horton MA, Lewis D, McNulty K. et al. Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res 1985; 45: 5663-5669.
• 16 Kamata T, Handa M, Takakuwa S. et al. Epitope Mapping for Monoclonal Antibody Reveals the Activation Mechanism for αvβ3 Integrin. PLoS One 2013; 8: e66096.
• 17 Santoso S, Kiefel V, Richter IG. et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta(3) integrin: the Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002; 99: 1205-1214.
• 18 Peterson JA, Gitter ML, Kanack A. et. Al. New low frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion 2010; 50: 324-333.
• 19 Kiefel V, Santoso S, Weisheit M. et al. Monoclonal antibody-specific immobilisation of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726.
• 20 Tamura K, Stecher G, Peterson D. et al. MEGA 6: Molecular Evolutionary Genetics Analysis Version 6.0. Mol Biol Evol 2013; 30: 2725-2729.
• 21 Calvete JJ.. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proc Soc Exp Biol Med 1995; 208: 346-360.
• 22 Newman PJ, Seligsohn U, Lyman S. et al. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA 1991; 88: 3160-3164.
• 23 Ruan J, Schmugge M, Kenneth JC. et al. Homozygous Cys542--> Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. Br J Haematol 1999; 105: 523-531.
• 24 Nurden AT, Pillois X, Fiore M. et al. Expanding the mutation spectrum affecting αIIbβ3 integrin in glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in large international cohort. Hum Mutat 2015; 36: 548-561.
• 25 Ambo H, Kamata T, Handa M. et al. Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol 1998; 102: 829-840.
• 26 Sachs UJ.. Fetal/neonatal alloimmune thrombocytopenia. Thromb Res 2013; 131 (Suppl. 01) S42-46.
• 27 Boval B, Bellucci S, Boyer-Neumann C. et al. Glanzmann's thrombasthenia and pregnancy: clinical observations and management of four affected women. Thromb Haemost 2001; 86: P1154 (Abstract).
• 28 Sundqvist SB, Nilsson IM, Svanberg L. et al. Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia. Scand J Haematol 1981; 27: 159-164.
• 29 Ito K, Yoshida H, Hatoyama H. et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple antiplatelet antibodies. Vox Sang 1991; 61: 40-46.
• 30 Tadokoro S, Tomiyama Y, Honda S. et al. Missense mutations in the β3 subunit have a different impact on the expression and function between αIIbβ3 and αvβ3. Blood 2002; 99: 931-938.
• 31 Mor-cohen R, Rosenberg N, Einav Y. et al. Unique disulfide bonds in epidermal growth factor (EGF) domains of b3 affect structure and function of αIIbβ3 and αvβ3 integrin in different manner. J Biol Chem 2012; 287: 8878-8891.
• 32 Zhu J, Luo BH, Xiao T. et al. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008; 32: 849-861.